Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 3

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

NCT05238519 · View on ClinicalTrials.gov ↗

Study Summary

The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as clinical and patient-reported outcomes. This study aims to promote optimal disease management and improve outcomes of FH patients.

Interventions

  • BEHAVIORAL Motivational interview (MI)

Study Locations (2)

Minnesota

  • Aspirus St. Luke's Hospital — Duluth
  • Essentia Health — Duluth

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2022-02-15
Est. Completion 2026-06
Phase Phase 3

Sponsor

Essentia Health

4 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05238519

The ClinicalTrials.gov registry entry for NCT05238519 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Essentia Health, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Genetic Disease appearing as the primary indexed condition, and to 1 intervention — of which Motivational interview (MI) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05238519 reports 2 study locations spanning 1 distinct geographic area — top geographies include Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05238519 about?

NCT05238519 is a clinical study titled "Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)". The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as ...

What is the current status of trial NCT05238519?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2022-02-15. Estimated completion is 2026-06.

What conditions does trial NCT05238519 study?

This clinical trial studies the following conditions: Genetic Disease, Familial Hypercholesterolemia, Cholesterol, Elevated. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05238519?

The interventions under investigation include: Motivational interview (MI) (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05238519?

This trial is sponsored by Essentia Health, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05238519 being conducted?

This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial